
CCRN Stock Forecast & Price Target
CCRN Analyst Ratings
Bulls say
Cross Country Healthcare has demonstrated stabilization in its gross margin, maintaining a rate of 20.0%, which is consistent with the previous quarter and surpasses prior estimates. Additionally, the company is set to be acquired by Aya Healthcare for $18.61 per share in cash, reflecting a significant 67% premium over its closing price before the announcement. This acquisition, expected to close in the second half of 2025, enhances Cross Country's valuation outlook amidst a positive financial backdrop.
Bears say
Cross Country Healthcare reported a significant decline in adjusted EBITDA, falling 44% year-over-year to $8.6 million in Q1/25, despite surprising on estimates due to revenue shortfalls. Additionally, the company’s Q1/25 revenue of $293.4 million was 23% lower than the previous year and did not meet both internal and consensus forecasts, reflecting ongoing weaker demand in the healthcare travel staffing sector. Consequently, revenue projections for 2025 have been revised downward to $1.166 billion, representing a decline of 13.3% from prior estimates.
This aggregate rating is based on analysts' research of Cross Country Healthcare and is not a guaranteed prediction by Public.com or investment advice.
CCRN Analyst Forecast & Price Prediction
Start investing in CCRN
Order type
Buy in
Order amount
Est. shares
0 shares